Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Reinhold Janocha"'
Autor:
Ana Giménez‐Arnau, Marcus Maurer, Jonathan Bernstein, Petra Staubach, Nathalie Barbier, Eva Hua, Thomas Severin, Yolandi Joubert, Reinhold Janocha, Maria‐Magdalena Balp
Publikováno v:
Clinical and Translational Allergy, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Background Chronic spontaneous urticaria (CSU) negatively impacts patients' sleep, thereby reducing health‐related quality of life (HRQoL). Half of patients with inadequately controlled CSU report sleep interference often or every night, w
Externí odkaz:
https://doaj.org/article/c654749ec2044c6fa71aef8c27a9caa8
Autor:
Jordis Trischler, Ivan Bottoli, Reinhold Janocha, Christoph Heusser, Xavier Jaumont, Phil Lowe, Aurelie Gautier, Abhijit Pethe, Ralph Woessner, Hans‐Günter Zerwes, Stefan Zielen
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 3, Pp n/a-n/a (2021)
Abstract Objective Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. T
Externí odkaz:
https://doaj.org/article/72f107318a284f9296f58eca83ccd8dc
Autor:
Sinisa Savic, I V Danilycheva, Alis Burciu, Avantika Barve, Ana Giménez-Arnau, Petra Staubach, Karl Sitz, Thomas Severin, Chia-Yu Chu, Michael Makris, Gordon Sussman, Jonathan A. Bernstein, Martin Metz, Marcus Maurer, Michihiro Hide, Eva Hua, Reinhold Janocha, Weily Soong
Background: Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c23593f71df398bcdf2c73e22822a6a4
Autor:
Ana Giménez‐Arnau, Marcus Maurer, Jonathan Bernstein, Petra Staubach, Nathalie Barbier, Eva Hua, Thomas Severin, Yolandi Joubert, Reinhold Janocha, Maria‐Magdalena Balp
Publikováno v:
Clinical and translational allergy. 12(2)
Background: Chronic spontaneous urticaria (CSU) negatively impacts patients' sleep, thereby reducing health-related quality of life (HRQoL). Half of patients with inadequately controlled CSU report sleep interference often or every night, which can l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4bcb90ac0fe8e59ddbb00b7495a14e
https://pubmed.ncbi.nlm.nih.gov/35218324
https://pubmed.ncbi.nlm.nih.gov/35218324
Autor:
Clive Grattan, Bettina Wedi, Wen-Hung Chung, Petra Staubach, R. Y. Meshkova, Karl Sitz, Sinisa Savic, Ana M Gimenez-Arnau, Gordon L Sussman, Randolf Brehler, I V Danilycheva, Kenneth Kobayashi, Jacques Hébert, Jonathan A. Bernstein, Chia-Yu Chu, Rodney Sinclair, Martin Metz, Jurgen Loffler, Michael Makris, Thomas Severin, Diane Baker, Reinhold Janocha, Andrea Bauer, Constance H. Katelaris, Eva Hua, Marcus Maurer, Avantika Barve
Publikováno v:
New England Journal of Medicine. 381:1321-1332
Background: In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized monoclonal anti-IgE antibody. Data are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63ae7b977e1f79ac75bb2374b6e8afeb
https://doi.org/10.1056/nejmoa1900408
https://doi.org/10.1056/nejmoa1900408
Two pivotal, randomized, double-blind studies in a chronic dermatology disease were ongoing when the COVID-19 pandemic broke out. The trials had identical design, with four parallel treatment arms: two doses of active drug, an active comparator and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba68c25506484a6d155fb98847d3359
Autor:
Christoph Heusser, Ivan Bottoli, Ralph Woessner, Jordis Trischler, Xavier Jaumont, Stefan Zielen, Reinhold Janocha, Abhijit Pethe, Hans-Günter Zerwes, Philip J. Lowe, Aurelie Gautier
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 3, Pp n/a-n/a (2021)
Clinical & Translational Immunology
Clinical & Translational Immunology
Objective Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. This multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d867d25955daccad2d4226dc16f0d362
https://pubmed.ncbi.nlm.nih.gov/33747510
https://pubmed.ncbi.nlm.nih.gov/33747510
Autor:
Maria-Magdalena Balp, Eva Hua, Nathalie Barbier, Ana Giménez-Arnau, Gordon Sussman, Marcus Maurer, Michihiro Hide, Karl Sitz, Reinhold Janocha, Thomas Severin, Martin Metz
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42d6eceeb680f4d29f975acbb64c2bcc
https://doi.org/10.1016/j.jaad.2021.06.259
https://doi.org/10.1016/j.jaad.2021.06.259
Autor:
Nathalie Barbier, Weily Soong, Thomas Severin, Eva Hua, Karl Sitz, Reinhold Janocha, Avantika Barve, Ana Giménez-Arnau, Jonathan A. Bernstein, Marcus Maurer
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a45124c82fb49cfad45efaf7931b5ca
https://doi.org/10.1016/j.jaad.2021.06.564
https://doi.org/10.1016/j.jaad.2021.06.564
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 147:A343-A344
Introduction Des donnees anterieures ont montre qu’une proportion elevee de patients atteints d’urticaire chronique spontanee (UCS) ont atteint un controle complet des symptomes avec un traitement par ligelizumab. Ici, nous rapportons l’efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05e3212037efb7bb3f96064d27a80eb5
https://doi.org/10.1016/j.annder.2020.09.534
https://doi.org/10.1016/j.annder.2020.09.534